Publications by authors named "Oliver Press"

Claim this Profile
M
Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma.
Victor A Chow, Ryan D Cassaday, Theodore A Gooley, Stephen D Smith, Brenda M Sandmaier, Oliver W Press

Blood Adv· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma.
Sherilyn A Tuazon, Brenda M Sandmaier, Theodore A Gooley, Darrell R Fisher, Leona A Holmberg, Oliver W Press

Bone Marrow Transplant· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma.
Sherilyn A Tuazon, Ryan D Cassaday, Theodore A Gooley, Brenda M Sandmaier, Leona A Holmberg, Oliver W Press

Transplant Cell Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and Y-DOTA.
Johnnie J Orozco, Aimee L Kenoyer, Yukang Lin, Shyril O'Steen, Rosario Guel, Oliver W Press

Mol Cancer Ther· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies.
Manuela Matesan, Darrell R Fisher, Roger Wong, Ajay K Gopal, Damian J Green, Oliver W Press

J Nucl Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-hodgkin lymphoma.
Victor A Chow, Joseph G Rajendran, Darrell R Fisher, Frederick R Appelbaum, Ryan D Cassaday, Oliver W Press

Am J Hematol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia.
Phuong Vo, Ted A Gooley, Joseph G Rajendran, Darrell R Fisher, Johnnie J Orozco, Oliver W Press

Haematologica· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk Lymphoma.
Ryan D Cassaday, Oliver W Press, John M Pagel, Joseph G Rajendran, Ted A Gooley

Clin Cancer Res· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.
Shyril O'Steen, Melissa L Comstock, Johnnie J Orozco, Donald K Hamlin, D Scott Wilbur, Oliver W Press

Blood· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report.
Haesook T Kim, Kwang Woo Ahn, Zhen-Huan Hu, Matthew S Davids, Virginia O Volpe, Oliver Press

Clin Cancer Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
Franck Morschhauser, Ian W Flinn, Ranjana Advani, Laurie H Sehn, Catherine Diefenbach, Oliver W Press

Lancet Haematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
cGMP production of astatine-211-labeled anti-CD45 antibodies for use in allogeneic hematopoietic cell transplantation for treatment of advanced hematopoietic malignancies.
Yawen Li, Donald K Hamlin, Ming-Kuan Chyan, Roger Wong, Eric F Dorman, Oliver W Press

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Xiaoyu Qu, Hongli Li, Rita M Braziel, Verena Passerini, Lisa M Rimsza, Oliver Press

Blood· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma.
Camille E Puronen, Ryan D Cassaday, Philip A Stevenson, Brenda M Sandmaier, Mary E Flowers, Oliver W Press

Biol Blood Marrow Transplant· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Lihua E Budde, David Wu, Daniel B Martin, Mary Philip, Andrei R Shustov, Oliver W Press

Br J Haematol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma.
Adam M Greenbaum, Damian J Green, Leona A Holmberg, Ted Gooley, Brian G Till, Oliver W Press

Blood Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Bruce D Cheson, Neil Chua, Jiri Mayer, Greg Dueck, Marek Trněný, Oliver Press

J Clin Oncol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort.
Lisa M Rimsza, Hongli Li, Rita M Braziel, Catherine M Spier, Daniel O Persky, Oliver W Press

Haematologica· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.
Mazyar Shadman, Hongli Li, Lisa Rimsza, John P Leonard, Mark S Kaminski, Oliver W Press

J Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
Paul M Barr, Hongli Li, W Richard Burack, Michael LeBlanc, Sonali M Smith, Oliver W Press

Lancet Haematol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma.
Yolanda D Tseng, Philip A Stevenson, Ryan D Cassaday, Andrew Cowan, Brian G Till, Oliver W Press

Biol Blood Marrow Transplant· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies.
Damian J Green, Shyril O'Steen, Yukang Lin, Melissa L Comstock, Aimee L Kenoyer, Oliver W Press

Blood· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions.
Sang Yun Lee, Philip Olsen, Dong Hoon Lee, Aimee L Kenoyer, Lihua E Budde, Oliver W Press

J Immunother· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.
Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till, Oliver Press

Clin Lymphoma Myeloma Leuk· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL.
Monika Pilichowska, Stefania Pittaluga, Judith A Ferry, Jessica Hemminger, Hong Chang, Oliver W Press

Blood Adv· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis